Phoundry Pharmaceuticals, Intarcia deal

Intarcia acquired Phoundry for an undisclosed sum. The deal gives Intarcia a portfolio of optimized peptides, which the company plans to use in combination with its ITCA 650 to develop once- or twice-yearly therapies to treat diabetes and obesity. Intarcia plans to start clinical studies by 2017 of multiple combinations that include ITCA 650. Intarcia said its pipeline now includes two ITCA 650 combinations with optimized peptides and one with an antibody fragment. ...